Scarica l'app Stockscreener
9.17
0.43%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXST Giù?
Forum
Previsione
Precedente Chiudi:
$9.22
Aprire:
$9.23
Volume 24 ore:
87,956
Relative Volume:
0.11
Capitalizzazione di mercato:
$377.25M
Reddito:
$128.29M
Utile/perdita netta:
$-30.69M
Rapporto P/E:
-11.18
EPS:
-0.82
Flusso di cassa netto:
$-27.17M
1 W Prestazione:
-7.74%
1M Prestazione:
-16.01%
6M Prestazione:
+16.65%
1 anno Prestazione:
-71.18%
Intervallo 1D:
$9.12
$9.362
Intervallo di 1 settimana:
$9.12
$10.05
Portata 52W:
$6.32
$34.71
Rxsight Inc Stock (RXST) Company Profile
Nome
Rxsight Inc
Settore
Industria
Telefono
949-521-7822
Indirizzo
100 COLUMBIA STREET, ALISO VIEJO
Confronta RXST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
9.175 | 379.10M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
107.21 | 188.27B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
94.03 | 138.83B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
356.52 | 135.60B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.04 | 129.09B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
82.47 | 48.51B | 5.88B | 1.34B | 799.60M | 2.3489 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Downgrade | Jefferies | Buy → Hold |
| 2025-07-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Iniziato | Piper Sandler | Neutral |
| 2025-04-09 | Downgrade | UBS | Buy → Neutral |
| 2025-04-04 | Downgrade | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-12-20 | Downgrade | Stifel | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-10-29 | Iniziato | Jefferies | Buy |
| 2024-08-20 | Reiterato | Needham | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-05-07 | Reiterato | BTIG Research | Buy |
| 2023-12-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Iniziato | Morgan Stanley | Overweight |
| 2023-04-13 | Iniziato | Oppenheimer | Outperform |
| 2022-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Iniziato | Needham | Buy |
Mostra tutto
Rxsight Inc Borsa (RXST) Ultime notizie
RxSight down on CFO transition - MSN
Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
Precision Trading with Rxsight Inc. (RXST) Risk Zones - Stock Traders Daily
RxSight (NASDAQ:RXST) Trading Down 0.9%Time to Sell? - MarketBeat
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - yourwyominglink.com
Decliners Report: Is RxSight Inc a potential multi bagger2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
How Recent Developments Are Shaping The RxSight (RXST) Investment Story - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - ACCESS Newswire
Expert Outlook: RxSight Through The Eyes Of 5 Analysts - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Institution Moves: What is RxSight Incs valuation compared to sectorTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
RxSight (RXST) soars 14.1%: Is further upside left in the stock? - MSN
RxSight stock price target raised to $11.50 from $11.00 at Jefferies - Investing.com Canada
RxSight stock price target raised to $11.50 from $11.00 at Jefferies By Investing.com - Investing.com South Africa
RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? - Nasdaq
RxSight Inc. (RXST) PT Raised to $11.50 at Jefferies - StreetInsider
RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO - VisionMonday.com
RxSight Announces New CFO and Strong Preliminary Results - TipRanks
Stifel reiterates Hold rating on RxSight stock amid competition concerns By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Stifel reiterates Hold rating on RxSight stock amid competition concerns - Investing.com
RxSight Up 11% on Preliminary Q4, Full Year Results - ocbj.com
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference By Investing.com - Investing.com South Africa
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference - Investing.com Nigeria
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga
RxSight (RXST) Reiterated at Neutral by UBS: 'Need More Regular Signs of Come-back' - StreetInsider
RxSight (RXST) Reiterated at Hold by Stifel Amid LAL, LDD Slowdown - StreetInsider
Benign Growth For RxSight, Inc. (NASDAQ:RXST) Underpins Stock's 30% Plummet - 富途牛牛
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance By Investing.com - Investing.com Nigeria
RxSight guides FY revenue above previous estimates, names new CFO - MSN
RxSight Sees Q4 Revenue Above View; Names Mark Wilterding CFO - Nasdaq
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance - Investing.com
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer - manilatimes.net
RxSight, Inc. Reports Preliminary Financial Results for Q4 and Full-Year 2025; Announces Appointment of New CFO - Quiver Quantitative
RxSight says Mark Wilterding appointed as CFO effective Jan 11, 2026 - marketscreener.com
RxSight Says Mark Wilterding Appointed As CFO Effective Jan 11, 2026 - TradingView — Track All Markets
RXSTRxsight, Inc. Latest Stock News & Market Updates - Stock Titan
RxSight, Inc. Appoints Mark Wilterding as Chief Financial Officer, Effective January 11, 2026 - marketscreener.com
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely - Sahm
RxSight, Inc. (RXST) Investor Outlook: A Close Look At Its 7.98% Potential Upside - DirectorsTalk Interviews
Is RxSight Inc. stock dividend yield sustainableJuly 2025 Institutional & Stepwise Entry/Exit Trade Alerts - Улправда
Is RxSight Inc. stock trading at a premium valuation2025 Fundamental Recap & Real-Time Buy Signal Alerts - Улправда
Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - marketscreener.com
Will RxSight Inc. stock outperform international peers2026 world cup usa national team group stage playmakers possession football tactical prediction tactical review - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ... - bdtonline.com
Rxsight Inc Azioni (RXST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):